Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trialArticle Published on 2022-11-022022-11-15 Journal: BMJ Open [Category] SARS, 진단, [키워드] approved assessment baseline Blood Cardiology case sery chronic fatigue syndrome chronic inflammation clinical clinical trial cognitive collected common COVID-19 defined domain double-blind dysfunction Effect effective Efficacy endothelial function Ethics evaluate fatigue healthy subject hyperbaric oxygen hypothese immunology IMPROVE Inconclusive independent individual initial institutional review board Long malaise mechanism monitoring board oxygen Oxygen therapy pandemic Patient peer-reviewed performed physical placebo-controlled placebo-controlled clinical trial positive Potential treatment product protocol Quality of life Questionnaires randomised rehabilitation medicine respiratory medicine (see thoracic medicine) secondary endpoint suggested survey Swedish Symptom syndrome the primary endpoint Treatment Trial VASCULAR MEDICINE. [DOI] 10.1136/bmjopen-2022-061870 PMC 바로가기
Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective studyArticle Published on 2022-10-132022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome administration anti-RBD antibody BNT-162b2 ChAdOx1 vaccine coronavirus coronavirus disease COVID-19 diabetes disease dose doses Effect Efficacy first dose IgG Immunity vaccine Immunoglobulin Infection kidney kidney transplant liver liver transplant Liver transplant. Local no difference older patient Organ transplant Patient platform Primary outcome Prospective Study prospectively studied question recipient reduced resulting SARS-CoV-2 SARS-CoV-2 vaccination second dose secondary endpoint seroconversion rate shown side significantly solid organ transplant spread to systemic adverse event the RBD the spike protein the vaccine trials unresponsiveness vaccination Vaccine vaccine doses vaccine platform [DOI] 10.1186/s12879-022-07764-x PMC 바로가기
Association of Different Malnutrition Parameters and Clinical Outcomes among COVID-19 Patients: An Observational StudyObservational Study Published on 2022-08-222022-10-05 Journal: Nutrients [Category] 임상, [키워드] 95% CI adjusted Admission age albumin albumin level Analysis analyzed association body mass index clinical Clinical outcome Comorbidity COVID-19 died Future Gender high risk Hospitalization Hospitalized In-hospital in-hospital mortality in-hospital outcomes increase in increased risk Inpatient IQR male Malnutrition median median age moderate Mortality mortality risk multivariable no risk nutritional risk screening 2002. Odds ratio parameter Patient patient population patients hospitalized patients with COVID-19 prevalent prognostic Regression analyses regression analysis Result risk risk factor Screening secondary endpoint Switzerland Treatment with COVID-19 [DOI] 10.3390/nu14163449 PMC 바로가기 [Article Type] Observational Study
Semiquantitative Chest CT Severity Score Predicts Failure of Noninvasive Positive-Pressure Ventilation in Patients Hospitalized for COVID-19 PneumoniaObservational Study Published on 2022-08-012022-10-04 Journal: Journal of cardiothoracic and vascular anesthesia [Category] 임상, [키워드] Analysis calculated Care Chest Chest computed tomography Chest CT confidence interval COVID-19 effective Endpoint Factor failure group Hospital admission In-hospital In-hospital death independent intubation measurement Mortality nine Non-invasive non-invasive ventilation observational study other variables oxygen Patient patients with COVID-19 Pneumonia pneumonia. primary endpoint receiver operator characteristics reported Respiratory Support responding poorly score secondary endpoint Treatment Ventilation [DOI] 10.1053/j.jvca.2021.09.010 PMC 바로가기 [Article Type] Observational Study
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trialRandomized Controlled Trial Published on 2022-08-012022-10-04 Journal: Inflammopharmacology [Category] COVID19(2023년), SARS, 임상, [키워드] accompanied addition administration admitted to ICU anti-inflammatory properties antioxidant Characteristics clinical complications Clinical improvement Clinical outcome control group coronavirus disease COVID-19 decrease Edaravone Endotracheal intubation Endpoint evaluate the effect Evaluating groups hallmark hospital ICUs immune response induce Injury intensive care unit intervention arms intervention group intravenous intubation Laboratory test mechanical ventilation Mechanical ventilation. Medical Science Mortality mortality rate National outcome overactive Patient Pneumonia Primary outcome Randomized randomized clinical trial receiving reduce secondary secondary endpoint severe COVID-19 severe COVID-19 patient single-center stimulate Tabriz therapy university viral infection [DOI] 10.1007/s10787-022-01001-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) for the treatment of severe COVID-19 pneumonia: First experience from AfricaClinical Trial Published on 2022-07-012022-10-05 Journal: PLoS ONE [Category] 임상, [키워드] 24 hour absence benefit cellular proliferation clinical benefit clinical trial Complete condition conducted COVID-19 CRP Cytokine storm D-dimer Day death defined demonstrated died discharge discharged dose Efficacy elevated enrolled feasibility feasible fraction High-resolution HRCT identify Inflammatory marker inhibit investigator-initiated Kenya low dose lung management mechanical ventilation median time on mechanical ventilation oxygen Oxygen requirement Oxygenation Patient patients PCR Pneumonia polymerase chain primary endpoint progressed radiation therapy remained resources SAE Safe secondary endpoint Sepsis severe COVID-19 Severe COVID-19 pneumonia the patient therapy Toxicity treat treated Treatment Trial university Vaccine were excluded [DOI] 10.1371/journal.pone.0270594 PMC 바로가기 [Article Type] Clinical Trial
The Effects of Theory-Based Educational Intervention and WhatsApp Follow-up on Papanicolaou Smear Uptake Among Postnatal Women in Malaysia: Randomized Controlled TrialRandomized Controlled Trial Published on 2022-06-272022-10-05 Journal: JMIR mHealth and uHealth [Category] 임상, [키워드] analyzed assigned Attitude baseline both group Cancer changed clinical clinics Cluster conducted control group control groups Controlled COVID-19 pandemic demonstrated determine Effect effective Effectiveness Factors first stage Follow-up form Google Health health knowledge high uptake IBM Intervention intervention group intervention study investigated knowledge knowledge score Malaysia mortality rate multifactorial Negeri Sembilan Neoplasms p value Papanicolaou test participant Patient Population Practice previous study primary endpoint proportion Psychological psychological theory questionnaire Randomized controlled trial Randomly reduce registry researcher secondary endpoint Self-efficacy shown Significant single-blind smear social media SPSS standard care statistically significant tested theory uptake uterine uterine cervical neoplasms. was used WhatsApp withdrawn women [DOI] 10.2196/32089 PMC 바로가기 [Article Type] Randomized Controlled Trial
Call, chosen, HA 2 T 2, ANDC: validation of four severity scores in COVID-19 patientsObservational Study Published on 2022-06-012022-10-04 Journal: Infection [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome age analysed Analysis association AUC Care Cohort Complete coronavirus COVID-19 COVID-19 patient death defined Disease progression external validation hospitalised ICU admission in-hospital mortality Infection invasive ventilation males management Mortality negative NPV Patient patients with COVID-19 polymerase chain Predictive primary endpoint risk Risk scores SARS-CoV-2 secondary endpoint Severity Score significantly Switzerland validation Validation study. [DOI] 10.1007/s15010-021-01728-0 PMC 바로가기 [Article Type] Observational Study
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study염증 표지자가 상승한 입원한 COVID-19 환자에서 토실리주맙의 조기 투여; COVIDSTORM-전향적, 무작위, 단일 센터, 공개 라벨 연구Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 바이오마커, 임상, 진단, [키워드] (interleukin-6 activities addition administration Admission benefit C-reactive protein clinical clinical recovery clinical status control group control patient control patients COVID-19 D-dimer demonstrated discharged elevated ferritin hospital Hospital admission Hospitalization Hospitalized hospitalized COVID-19 patient Hypoxemia immune response Inflammation inflammation markers Inflammatory inflammatory biomarkers intensive care intensive care unit admission interleukin interleukin-6 interquartile range marker median Open-label Ordinal Scale Patient patients hospitalized primary endpoint Randomized respiratory Respiratory Support SARS-CoV-2 secondary endpoint Secondary endpoints seven-category ordinal scale severe COVID-19 significantly SOC Standard of care TCZ Tocilizumab tocilizumab. with COVID-19 [DOI] 10.1016/j.cmi.2022.02.027 PMC 바로가기 [Article Type] Randomized Controlled Trial
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor protease inhibitor. Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial